Neuroprotective Agents for Management of Parkinson’s disease
Abstract
#No Abstract#
Jankovic J. Etiology and pathogenesis of Parkinson disease. In: D. S. Basow (Ed.), UpToDate. Retrieved from http://www.uptodate.com/home/index. html.
Ernst M, Gottwald M. Parkinson’s Disease and Other Movement Disorders. In: Alldrege B, Corelli R, Ernst M,editors. Applied therapeutics, the clinical use of drugs, Philadelphia: Wolters Kluwer, 2011; p 1358-80.
Hague S, Klaffke S , Bandmann O. Neurodegenerative disorders: Parkinson’s disease and Huntington’s disease. J Neurol Neurosurg Psychiatry. 2005;76;1058-63.
Tsang AH, Chung KK. Oxidative and nitrosative stress in Parkinson’s disease. Biochimica Biophysica Acta. 2009;1792(7); 643–50.
Yokoyama H, Kuroiwa H, Yano R, Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson’s disease. Neurol Sci. 2008; 29:293–301.
Hirsch EC, Hunot S. Neuroinflammation in Parkinson’s disease: a target for neuroprotection. Lancet Neurol. 2009; 8(4):382-97.
Tarsy D. Neuroprotective therapy for Parkinson disease. In: D. S. Basow (Ed.), UpToDate. Retrieved from http://www.uptodate.com/home/index. html.
Stern MB. The early treatment of Parkinson’s disease: levodopa, dopamine agonists or both. Parkinsonism Relat Disord. 2000; 7(1):27-33.
Maccioni R, Muoz J, Barbeito L.The molecular basis of Alzheimer’s disease and other neurodegenerative disorders. Arch Med Res. 2001; 32: 367-81.
Park S, Geddes TJ, Javitch JA, Kuhn DM. Dopamine prevents nitration of tyrosine hydroxylase by peroxynitrite and nitrogen dioxide. J Biol Chem. 2003; 278: 28736- 42.
Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz S, Weiner W. Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66: 976-82.
Boll MC, Alcaraz-Zubeldia M, Rios C. Medical Management of Parkinson’s Disease: Focus on Neuroprotection. Curr Neuropharmacol. 2011; 9(2):350- 9.
Tarsy D. Pharmacologic treatment of Parkinson disease. In: D. S. Basow (Ed.), UpToDate. Retrieved from http://www.uptodate.com/home/index. html.
Murata M. Pharmacologic treatment of Parkinson disease. Brain Nerve. 2009; 61(4):464-72.
Seidl SE, Potashkin JA. The promise of neuroprotective agents in parkinson’s disease. Front Neurol. 2011; 2:68.
Verhave PS, Jongsma MJ, Van Den Berg RM, Vanwersch RAP, Smit AB, Philippens IH. Neuroprotective effects of riluzole in early phase Parkinson’s disease on clinically relevant parameters in the marmoset MPTP model. Neuropharmacology. 2012; 62(4):1700-7
Clark J, Clore E, Zheng K, Adame A, Masliah E, Simon D. Oral N-Acetyl- Cysteine Attenuates Loss of Dopaminergic Terminals in a-Synuclein Overexpressing Mice. PLoS ONE 2010; 5(8): e12333.
Lu M, Hu G. Targeting metabolic inflammation in Parkinson’s disease: implications for prospective therapeutic strategies. Clin Exp Pharmacol Physiol. 2012; 39(6):577-85.
Magrone T, Marzulli G, Jirillo E. Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products. Curr Pharm Des. 2012; 18(1):34-42.
Ho YS, Poon DC, Chan TF, Chang RC. From Small to Big Molecules: How Do We Prevent and Delay the Progression of Age- Related Neurodegeneration? Curr Pharm Des. 2012;18(1):15-26.
Mandel SA, Weinreb O, Amit T, Youdim MB. The importance of the multiple target action of green tea polyphenols for neuroprotection. Front Biosci (Schol Ed). 2012; 4:581-98.
| Files | ||
| Issue | Vol 1, No 1 (Winter 2013) | |
| Section | Focus | |
| Keywords | ||
| #No Keywords# | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
